

Connecticut HB 6669

Lifyorli® (relacorilant) Capsules for Oral Use

Corcept Therapeutics provides the following information to Connecticut prescribers, as required by Connecticut House Bill 6669.

The pricing information below reflects Corcept Therapeutics Wholesale Acquisition Costs ("WAC") for their product: Lifyorli. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Lifyorli

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	PACKAGE SIZE	WHOLESALE ACQUISITION COST (WAC)
Lifyorli® 150 mg 9-Dose Supply	76346-550-09	Capsule, one 100 mg and two 25 mg	27 Capsules	\$39,226.50
Lifyorli® 150 mg 1-Dose Supply	76346-450-01	Capsule, one 100 mg and two 25 mg	3 Capsules	\$4,358.50
Lifyorli® 125 mg 9-Dose Supply	76346-525-09	Capsule, one 100 mg and one 25 mg	18 Capsules	\$39,226.50
Lifyorli® 125 mg 1-Dose Supply	76346-425-01	Capsule, one 100 mg and one 25 mg	2 Capsules	\$4,358.50

Generic versions of Lifyorli are not currently available. Connecticut law further requires disclosure of Information on the variation of efficacy of the legend drug marketed to different racial and ethnic groups, if such information is available. In this case, there is no additional information available about Lifyorli regarding efficacy in different racial or ethnic groups.

Lifyorli is a registered trademark of Corcept Therapeutics Incorporated.

© 2026 Corcept Therapeutics Incorporated. All rights reserved.

US-REL-26-0098 10-26